Genetic/JJ
Hearing/NN
Loss/NN
and/CC
Gene/NN
Therapy/NN
./.
====================
Genetic/JJ
hearing/VBG
loss/NN
crosses/NNS
almost/RB
all/DT
the/DT
categories/NNS
of/IN
hearing/JJ
loss/NN
which/WDT
includes/VBZ
the/DT
following/VBG
:/:
conductive/JJ
,/,
sensory/JJ
,/,
and/CC
neural/JJ
;/:
syndromic/JJ
and/CC
nonsyndromic/JJ
;/:
congenital/JJ
,/,
progressive/JJ
,/,
and/CC
adult/JJ
onset/NN
;/:
high-frequency/RB
,/,
low-frequency/RB
,/,
or/CC
mixed/JJ
frequency/NN
;/:
mild/JJ
or/CC
profound/JJ
;/:
and/CC
recessive/JJ
,/,
dominant/JJ
,/,
or/CC
sex-linked/JJ
./.
====================
Genes/NNS
play/VBP
a/DT
role/NN
in/IN
almost/RB
half/NN
of/IN
all/DT
cases/NNS
of/IN
hearing/JJ
loss/NN
but/CC
effective/JJ
treatment/NN
options/NNS
are/VBP
very/RB
limited/JJ
./.
====================
Genetic/JJ
hearing/NN
loss/NN
is/VBZ
considered/VBN
to/TO
be/VB
extremely/RB
genetically/RB
heterogeneous/JJ
./.
====================
The/DT
advancements/NNS
in/IN
genomics/NNS
have/VBP
been/VBN
instrumental/JJ
to/TO
the/DT
identification/NN
of/IN
more/RBR
than/IN
6,000/CD
causative/JJ
variants/NNS
in/IN
more/RBR
than/IN
150/CD
genes/NNS
causing/VBG
hearing/JJ
loss/NN
./.
====================
Identification/NN
of/IN
genes/NNS
for/IN
hearing/JJ
impairment/NN
provides/VBZ
an/DT
increased/VBN
insight/NN
into/IN
the/DT
normal/JJ
development/NN
and/CC
function/NN
of/IN
cells/NNS
in/IN
the/DT
auditory/JJ
system/NN
./.
====================
These/DT
defective/JJ
genes/NNS
will/MD
ultimately/RB
be/VB
important/JJ
therapeutic/JJ
targets/NNS
./.
====================
However/RB
,/,
the/DT
auditory/JJ
system/NN
is/VBZ
extremely/RB
complex/NN
which/WDT
requires/VBZ
tremendous/JJ
advances/NNS
in/IN
gene/NN
therapy/NN
including/VBG
gene/NN
vectors/NNS
,/,
routes/NNS
of/IN
administration/NN
,/,
and/CC
therapeutic/JJ
approaches/NNS
./.
====================
This/DT
review/NN
summarizes/VBZ
and/CC
discusses/VBZ
recent/JJ
advances/NNS
in/IN
elucidating/VBG
the/DT
genomics/NNS
of/IN
genetic/JJ
hearing/NN
loss/NN
and/CC
technologies/NNS
aimed/VBD
at/IN
developing/VBG
a/DT
gene/NN
therapy/NN
that/IN
may/MD
become/VB
a/DT
treatment/NN
option/NN
for/IN
in/IN
the/DT
near/JJ
future/JJ
./.
====================
The/DT
World/NN
Health/NN
Organization/NN
reported/VBD
that/IN
466/CD
million/NN
people/NN
worldwide/NN
suffers/NNS
from/IN
hearing/JJ
loss/NN
and/CC
estimated/VBN
to/TO
rise/VB
over/IN
900/CD
million/NN
by/IN
2050/CD
[/(
1/CD
]/)
./.
====================
Hearing/VBG
loss/NN
means/NNS
not/RB
able/JJ
to/TO
hear/JJ
as/IN
well/RB
as/IN
someone/RB
with/IN
normal/JJ
hearing/JJ
or/CC
a/DT
hearing/JJ
threshold/JJ
of/IN
more/RBR
than/IN
25/CD
decibels/VBZ
in/IN
one/CD
or/CC
both/CC
ears/VBZ
./.
====================
Hearing/VBG
loss/NN
can/MD
also/RB
be/VB
classified/VBN
as/IN
either/CC
conductive/JJ
,/,
sensorineural/JJ
or/CC
mixed/JJ
hearing/NN
loss/NN
./.
====================
Conductive/JJ
hearing/JJ
loss/NN
is/VBZ
when/WRB
there/EX
is/VBZ
a/DT
problem/NN
conducting/VBG
the/DT
sound/JJ
waves/NNS
along/IN
the/DT
outer/JJ
ear/JJ
,/,
tympanic/JJ
membrane/NN
(/(
eardrum/FW
)/)
and/CC
ossicular/JJ
chain/NN
of/IN
the/DT
middle/JJ
ear/JJ
towards/IN
the/DT
cochlea/NN
./.
====================
Sensorineural/JJ
hearing/JJ
loss/NN
(/(
SNHL/NN
)/)
is/VBZ
when/WRB
there/EX
is/VBZ
problem/NN
translating/VBG
the/DT
sound/JJ
vibrations/NNS
into/IN
electrical/JJ
signals/NNS
in/IN
the/DT
sensory/JJ
hair/NN
cells/NNS
(/(
HCs/NNS
)/)
inside/NN
the/DT
cochlear/JJ
or/CC
damage/NN
in/IN
transmitting/VBG
the/DT
information/NN
involving/VBG
the/DT
afferent/JJ
nerves/NNS
towards/IN
the/DT
brain/NN
./.
====================
This/DT
communication/NN
between/IN
the/DT
ear/JJ
and/CC
brain/NN
can/MD
be/VB
damaged/VBN
by/IN
aging/VBG
,/,
acoustic/JJ
overexposure/JJ
and/CC
ototoxic/JJ
drugs/NNS
./.
====================
Heredity/RB
also/RB
plays/VBZ
a/DT
big/NN
part/NN
wherein/IN
genes/NNS
for/IN
hearing/JJ
are/VBP
mutated/VBN
or/CC
genes/NNS
may/MD
increase/VB
the/DT
susceptibility/NN
to/TO
ear/JJ
damage/NN
or/CC
deterioration/NN
from/IN
aging/NN
./.
====================
Hearing/VBG
loss/NN
causes/VBZ
an/DT
annual/JJ
global/JJ
deficit/NN
of/IN
US/NN
$/CD
750/CD
billion/NN
[/(
2/CD
]/)
which/WDT
offers/VBZ
a/DT
high/JJ
demand/CC
for/IN
an/DT
effective/JJ
solution/NN
./.
====================
Conductive/JJ
hearing/JJ
loss/NN
can/MD
be/VB
surgically/RB
managed/JJ
in/IN
most/JJS
patients/NNS
./.
====================
In/IN
contrast/NN
,/,
SNHL/NN
is/VBZ
mostly/RB
irreversible/JJ
and/CC
results/VBZ
in/IN
permanent/JJ
hearing/NN
loss/NN
./.
====================
However/RB
,/,
hearing/JJ
rehabilitation/NN
is/VBZ
possible/JJ
thru/NN
hearing/JJ
devices/VBZ
that/DT
can/MD
either/CC
be/VB
worn/NN
externally/RB
or/CC
implanted/JJ
./.
====================
Despite/IN
the/DT
advances/NNS
in/IN
hearing/JJ
aid/VB
and/CC
cochlear/JJ
implant/JJ
technologies/NNS
,/,
the/DT
quality/NN
of/IN
perceived/VBN
sound/JJ
still/RB
can/MD
not/RB
mimic/VB
that/DT
of/IN
the/DT
normal/JJ
ear/JJ
./.
====================
Impaired/JJ
speech/NN
perception/NN
in/IN
noisy/NN
environments/NNS
and/CC
musical/JJ
sound/JJ
perception/NN
are/VBP
the/DT
biggest/JJS
hurdles/NNS
of/IN
cochlear/JJ
implants/NNS
[/(
3/CD
,/,
4/CD
]/)
./.
====================
Scientist/NN
around/IN
the/DT
world/NN
are/VBP
working/VBG
on/IN
genomics-based/VBN
research/NN
and/CC
development/NN
in/IN
hearing/JJ
science/NN
./.
====================
In/IN
this/DT
review/NN
,/,
we/PRP
consolidated/VBD
the/DT
genes/NNS
that/WDT
are/VBP
currently/RB
identified/VBN
to/TO
be/VB
associated/VBN
with/IN
hearing/JJ
loss/NN
./.
====================
We/PRP
reviewed/VBD
ways/NNS
in/IN
which/WDT
genes/NNS
are/VBP
used/VBN
to/TO
restore/VB
or/CC
protect/VB
hearing/JJ
and/CC
ways/NNS
to/TO
deliver/VB
the/DT
genes/NNS
to/TO
their/PRP$
target/NN
cells/NNS
such/JJ
as/IN
viral/JJ
and/CC
non-viral/JJ
vectors/NNS
./.
====================
We/PRP
also/RB
discussed/VBN
the/DT
various/JJ
strategies/NNS
used/VBN
in/IN
gene/NN
therapy/NN
such/JJ
as/IN
gene/NN
replacement/NN
,/,
slicing/JJ
and/CC
editing/VBG
./.
====================
Syndromic/JJ
vs./CC
nonsyndromic/JJ
hearing/JJ
loss/NN
====================
Clinically/RB
,/,
hearing/VBG
impairment/NN
may/MD
be/VB
associated/VBN
with/IN
other/JJ
disorders/NNS
(/(
syndromic/JJ
)/)
or/CC
it/PRP
may/MD
only/RB
be/VB
a/DT
symptom/JJ
(/(
nonsyndromic/JJ
)/)
./.
====================
Syndromic/JJ
hearing/JJ
loss/NN
occurs/VBZ
with/IN
malformations/NNS
of/IN
the/DT
external/JJ
ear/JJ
,/,
together/RB
with/IN
other/JJ
malformations/NNS
in/IN
other/JJ
organs/NNS
or/CC
organ/NN
systems/NNS
./.
====================
Nonsyndromic/JJ
hearing/JJ
loss/NN
has/VBZ
no/DT
associated/VBN
visible/JJ
deformities/VBZ
or/CC
the/DT
external/JJ
ear/JJ
or/CC
any/DT
related/JJ
medical/JJ
conditions/NNS
,/,
but/CC
could/MD
be/VB
associated/VBN
with/IN
problems/NNS
of/IN
the/DT
middle/JJ
or/CC
inner/JJ
ear/JJ
./.
====================
Deafness/RB
genes/NNS
====================
Genes/NNS
are/VBP
responsible/JJ
for/IN
hearing/JJ
loss/NN
among/IN
50/CD
%/NN
–60/CD
%/NN
of/IN
children/NN
born/JJ
with/IN
hearing/JJ
loss/NN
[/(
5/CD
]/)
./.
====================
According/VBG
to/TO
the/DT
Hereditary/JJ
Hearing/JJ
Loss/NN
Homepage/NN
[/(
6/CD
]/)
to/TO
date/NN
,/,
there/EX
is/VBZ
a/DT
total/JJ
of/IN
112/CD
non-syndromic/JJ
hearing/JJ
loss/NN
genes/NNS
that/WDT
has/VBZ
been/VBN
identified/VBN
(/(
Fig/NN
./.
====================
1/CD
)/)
,/,
71/CD
autosomal/JJ
recessive/JJ
(/(
Table/JJ
1/CD
)/)
[/(
7–125/CD
]/)
,/,
45/CD
autosomal/JJ
dominant/JJ
(/(
Table/JJ
2/CD
)/)
[/(
126–207/CD
]/)
,/,
and/CC
5/CD
X-linked/JJ
and/CC
1/CD
non-syndromic/JJ
genes/NNS
(/(
Table/JJ
3/CD
)/)
[/(
208–218/CD
]/)
./.
====================
The/DT
most/JJS
common/JJ
cause/VBP
of/IN
severe-to-profound/JJ
nonsyndromic/JJ
hearing/JJ
loss/NN
in/IN
most/JJS
populations/NNS
is/VBZ
the/DT
autosomal/JJ
recessive/JJ
mutation/NN
of/IN
GJB2/NN
./.
====================
While/IN
the/DT
most/JJS
common/JJ
cause/VBP
of/IN
mild-to-moderate/JJ
hearing/JJ
loss/NN
is/VBZ
the/DT
autosomal/JJ
recessive/JJ
mutation/NN
on/IN
STRC/NN
[/(
219/CD
]/)
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
About/RB
30/CD
%/NN
of/IN
inherited/VBN
hearing/NN
loss/NN
is/VBZ
associated/VBN
with/IN
a/DT
syndrome/NN
[/(
220/CD
]/)
./.
====================
Syndromic/JJ
hearing/JJ
impairment/NN
tends/NNS
to/TO
be/VB
less/RBR
genetically/RB
heterogeneous/JJ
than/IN
nonsyndromic/JJ
,/,
but/CC
more/RBR
than/IN
one/CD
locus/NN
has/VBZ
been/VBN
identified/VBN
for/IN
several/JJ
syndromes/NNS
./.
====================
There/EX
are/VBP
currently/RB
11/CD
syndromes/NNS
(/(
Table/JJ
4/CD
)/)
[/(
221–265/CD
]/)
associated/VBN
with/IN
hearing/JJ
loss/NN
with/IN
a/DT
total/JJ
of/IN
47/CD
syndromic/JJ
hearing/JJ
loss/NN
genes/NNS
with/IN
27/CD
autosomal/JJ
recessive/JJ
,/,
13/CD
autosomal/JJ
dominant/JJ
,/,
4/CD
autosomal/JJ
dominant/JJ
or/CC
recessive/JJ
and/CC
2/CD
X-linked/JJ
recessive/JJ
pattern/NN
of/IN
inheritance/NN
./.
====================
Relevance/NN
of/IN
genomics/NNS
in/IN
hearing/JJ
loss/NN
====================
With/IN
the/DT
rapid/JJ
advancement/JJ
of/IN
genomics/NNS
,/,
it/PRP
became/VBD
possible/JJ
to/TO
establish/VB
high-resolution/JJ
genetic/JJ
and/CC
physical/JJ
maps/VBZ
,/,
genomic/JJ
and/CC
cDNA/NN
libraries/NNS
which/WDT
made/VBD
it/PRP
easier/RBR
to/TO
correlate/VB
the/DT
genes/NNS
for/IN
hearing/JJ
loss/NN
./.
====================
The/DT
establishment/NN
of/IN
the/DT
human/JJ
fetal/JJ
cochlear/NN
cDNA/NN
library/NN
gave/VBD
way/NN
to/TO
the/DT
cloning/NN
of/IN
majority/NN
of/IN
the/DT
genes/NNS
identified/VBN
related/JJ
to/TO
hearing/JJ
loss/NN
[/(
266/CD
]/)
./.
====================
Screening/VBG
strategies/NNS
can/MD
be/VB
made/VBN
in/IN
combination/NN
with/IN
next-generation/JJ
sequencing/NN
platforms/NNS
to/TO
study/VB
sets/NNS
of/IN
deafness/JJ
subjects/NNS
who/WP
are/VBP
likely/JJ
to/TO
have/VB
the/DT
same/JJ
defective/JJ
gene/NN
to/TO
effectively/RB
diagnose/VBP
patients/NNS
with/IN
genetic/JJ
hearing/NN
loss/NN
[/(
267/CD
]/)
./.
====================
Gene/NN
Therapy/NN
====================
As/IN
mentioned/VBN
above/JJ
,/,
genetic/JJ
hearing/NN
loss/NN
can/MD
now/RB
be/VB
screened/VBN
in/IN
utero/FW
./.
====================
In/IN
principle/NN
,/,
gene/NN
therapy/NN
can/MD
fix/JJ
a/DT
genetic/JJ
mutation/NN
like/IN
the/DT
ones/NNS
involving/VBG
hearing/JJ
genes/NNS
removing/VBG
or/CC
replacing/VBG
the/DT
defective/JJ
gene/NN
or/CC
supplying/VBG
the/DT
absent/JJ
gene/NN
./.
====================
However/RB
,/,
compared/VBN
to/TO
other/JJ
target/NN
organs/NNS
for/IN
gene/NN
therapy/NN
,/,
there/EX
are/VBP
several/JJ
obstacles/NNS
related/JJ
to/TO
the/DT
anatomy/NN
of/IN
the/DT
inner/JJ
ear/JJ
./.
====================
The/DT
cochlea/NN
is/VBZ
a/DT
spiraled/JJ
and/CC
fluid-filled/JJ
cavity/NN
in/IN
a/DT
bony/NN
labyrinth/NN
that/DT
is/VBZ
very/RB
vulnerable/JJ
to/TO
changes/NNS
which/WDT
affect/VBP
the/DT
conversion/NN
of/IN
sound/JJ
vibration/NN
into/IN
electrical/JJ
signals/NNS
./.
====================
Consequently/RB
,/,
maintaining/VBG
this/DT
homeostasis/NN
is/VBZ
the/DT
biggest/JJS
challenge/NN
in/IN
delivering/VBG
any/DT
kind/JJ
of/IN
therapeutic/JJ
products/NNS
into/IN
the/DT
inner/JJ
ear/JJ
./.
====================
Different/JJ
routes/NNS
of/IN
administration/NN
have/VBP
been/VBN
explored/VBN
with/IN
various/JJ
purposes/NNS
,/,
such/JJ
as/IN
efficiency/NN
in/IN
transduction/NN
and/CC
reduced/VBD
cochlear/JJ
toxicity/NN
./.
====================
The/DT
most/JJS
successful/JJ
way/NN
to/TO
deliver/VB
therapeutic/JJ
agents/NNS
to/TO
the/DT
cochlea/NN
is/VBZ
an/DT
intracochlear/JJ
approach/NN
through/IN
the/DT
round/NN
window/NN
membrane/NN
(/(
RWM/NN
)/)
./.
====================
The/DT
RWM/NN
is/VBZ
a/DT
semipermeable/JJ
soft/JJ
tissue/NN
separating/VBG
the/DT
middle/JJ
and/CC
inner/JJ
ear/JJ
./.
====================
It/PRP
allows/VBZ
low/JJ
molecular/JJ
weight/NN
molecules/NNS
to/TO
up/RB
to/TO
molecules/NNS
with/IN
molecular/JJ
weight/NN
45,000/CD
under/IN
normal/JJ
physiological/JJ
conditions/NNS
[/(
268/CD
]/)
./.
====================
Direct/JJ
injection/NN
through/IN
the/DT
RWM/NN
can/MD
also/RB
be/VB
done/VBN
with/IN
a/DT
microsyringe/NN
and/CC
a/DT
narrow-gauge/JJ
needle/NN
./.
====================
Another/DT
option/NN
is/VBZ
to/TO
insert/VB
material/JJ
inside/NN
the/DT
cochlear/JJ
cavity/NN
to/TO
create/VB
an/DT
opening/VBG
,/,
in/IN
a/DT
procedure/NN
called/VBN
a/DT
cochleostomy/NN
./.
====================
This/DT
was/VBD
the/DT
approach/NN
used/VBN
by/IN
our/PRP$
group/NN
to/TO
inject/VB
material/JJ
into/IN
the/DT
three/CD
cochlear/JJ
cavities/NNS
(/(
scala/NN
vestibule/NN
,/,
scala/NN
media/NNS
,/,
and/CC
scala/NN
tympani/NNS
)/)
[/(
269/CD
,/,
270/CD
]/)
./.
====================
Viral/JJ
vs./CC
non-viral/JJ
gene/NN
delivery/NN
====================
Gene/NN
transfection/NN
to/TO
inner/JJ
ear/JJ
cells/NNS
have/VBP
mostly/RB
utilized/VBN
replication/NN
defective/JJ
viral/JJ
vectors/NNS
(/(
Table/JJ
5/CD
)/)
[/(
274–280/CD
]/)
./.
====================
For/IN
example/NN
,/,
adenoviruses/NNS
were/VBD
used/VBN
to/TO
transfer/VB
gene/NN
markers/NNS
such/JJ
as/IN
β-galactosidase/RB
and/CC
red/JJ
fluorescent/JJ
protein/NN
as/IN
well/RB
as/IN
functional/JJ
genes/NNS
such/JJ
as/IN
glial-derived/JJ
neurotrophic/JJ
factor/NN
(/(
GDNF/NN
)/)
to/TO
the/DT
auditory/JJ
system/NN
[/(
270/CD
,/,
281/CD
,/,
282/CD
]/)
./.
====================
Another/DT
example/NN
is/VBZ
the/DT
use/NN
of/IN
adeno-associated/JJ
viral/JJ
vectors/NNS
(/(
AAV/NN
)/)
,/,
such/JJ
as/IN
AAV1/NN
,/,
2/CD
,/,
6/CD
,/,
8/CD
,/,
and/CC
Anc80L65/NN
,/,
which/WDT
showed/VBD
greater/JJR
transfection/NN
efficiency/NN
in/IN
inner/JJ
ear/JJ
delivery/NN
[/(
283/CD
]/)
./.
====================
Recently/RB
,/,
the/DT
USH1/NN
protein/NN
network/NN
component/NN
harmonin/NN
(/(
USH1C/NN
)/)
gene/NN
delivery/NN
using/VBG
synthetic/JJ
Anc80L65/NN
vectors/NNS
to/TO
treat/VB
hearing/JJ
loss/NN
in/IN
mice/NNS
with/IN
Usher/DT
syndrome/NN
restored/VBD
complex/NN
auditory/JJ
and/CC
balance/NN
behaviour/NN
similar/JJ
to/TO
near/JJ
wild-type/JJ
levels/NNS
with/IN
up/RB
to/TO
90/CD
%/NN
transduction/NN
efficiency/NN
[/(
276/CD
]/)
./.
====================
AAV2/8/DT
vectors/NNS
that/IN
encode/VBP
wild-type/JJ
whirlin/NN
(/(
WHRN/NN
)/)
gene/NN
restored/VBD
inner/JJ
hair/NN
cells/NNS
(/(
IHC/NN
)/)
but/CC
not/RB
outer/RBR
hair/NN
cells/NNS
(/(
OHC/NN
)/)
and/CC
auditory/JJ
function/NN
[/(
272/CD
]/)
./.
====================
AAV2/1/NN
vectors/NNS
were/VBD
injected/VBN
in/IN
transmembrane/JJ
channel/NN
like/IN
1/CD
(/(
TMC1/NN
)/)
mutant/JJ
mice/NNS
restored/VBD
moderate/JJ
hearing/JJ
function/NN
with/IN
minimal/JJ
auditory-brainstem-response/JJ
threshold/NN
[/(
284/CD
]/)
./.
====================
A/DT
similar/JJ
viral/JJ
capsid/NN
and/CC
a/DT
promoter/NN
that/WDT
restricted/JJ
expression/NN
to/TO
IHCs/NNS
partially/RB
restored/VBD
auditory/JJ
function/NN
in/IN
mice/NNS
deficient/JJ
in/IN
the/DT
IHC/NN
gene/NN
encoding/VBG
for/IN
vesicular/JJ
glutamate/NN
transporter/JJR
3/CD
(/(
VGluT3/NN
)/)
[/(
271/CD
]/)
./.
====================
Furthermore/RB
,/,
the/DT
cellular/JJ
tropism/NN
of/IN
a/DT
novel/JJ
adeno-associated/JJ
bovine/JJ
virus/NN
vector/NN
efficiently/RB
transduced/VBN
cochlear/JJ
and/CC
vestibular/JJ
HC/NN
and/CC
supporting/VBG
cells/NNS
without/IN
pathological/JJ
effects/NNS
outperforming/VBG
other/JJ
viral/JJ
vectors/NNS
[/(
285/CD
]/)
./.
====================
The/DT
concept/NN
of/IN
gene/NN
therapy/NN
seems/VBZ
straightforward/JJ
,/,
but/CC
numerous/JJ
problems/NNS
and/CC
risks/NNS
exist/VBP
that/IN
prevent/VBP
gene/NN
therapy/NN
using/VBG
viral/JJ
vectors/NNS
[/(
286/CD
]/)
./.
====================
Even/RB
with/IN
all/DT
the/DT
potential/JJ
benefits/VBZ
of/IN
gene/NN
therapy/NN
,/,
the/DT
utilization/NN
of/IN
viral/JJ
vectors/NNS
in/IN
the/DT
clinical/JJ
setup/NN
is/VBZ
hindered/VBN
by/IN
the/DT
possibility/NN
of/IN
tumorigenesis/NN
and/CC
unexpected/JJ
adverse/JJ
effects/NNS
from/IN
virus/NN
integration/NN
in/IN
human/JJ
DNA/NN
./.
====================
Therefore/RB
,/,
non-viral/JJ
delivery/NN
systems/NNS
are/VBP
developed/VBN
as/IN
an/DT
alternative/JJ
to/TO
harness/VB
gene/NN
therapy/NN
./.
====================
These/DT
non-viral/JJ
vectors/NNS
include/VBP
cationic/NN
liposomes/NNS
and/CC
other/JJ
non-liposomal/JJ
polymers/NNS
along/IN
with/IN
the/DT
use/NN
of/IN
biolistic/JJ
materials/NNS
and/CC
electroporation/NN
(/(
Table/JJ
6/CD
)/)
[/(
287–301/CD
]/)
./.
====================
Cationic/JJ
liposomes/NNS
are/VBP
phospholipid/JJ
vesicles/NNS
that/DT
fuses/VBZ
to/TO
the/DT
cellular/JJ
membrane/NN
due/JJ
to/TO
their/PRP$
cationic/JJ
charge/NN
,/,
thereby/RB
releasing/VBG
the/DT
DNA/NN
to/TO
the/DT
cytoplasm/NN
[/(
302/CD
]/)
./.
====================
Cationic/JJ
liposomes/NNS
can/MD
be/VB
easily/RB
prepared/VBN
in/IN
large/JJ
amounts/NNS
,/,
non-infectious/JJ
and/CC
has/VBZ
a/DT
large/JJ
gene/NN
capacity/NN
./.
====================
Meanwhile/DT
,/,
synthetic/JJ
and/CC
naturally/RB
occurring/VBG
polycationic/JJ
polymers/NNS
attract/NN
negatively/RB
charged/VBN
phosphates/NNS
of/IN
the/DT
DNA/NN
[/(
303/CD
]/)
./.
====================
These/DT
include/VBP
polyethylenimine/NN
,/,
dextran/NN
,/,
chitosan/NN
,/,
PLGA/NN
and/CC
among/IN
others/NNS
./.
====================
Cationic/JJ
polymers/NNS
are/VBP
also/RB
easy/RB
to/TO
prepare/VB
and/CC
non-immunogenic/JJ
./.
====================
However/RB
,/,
both/CC
types/NNS
have/VBP
low/JJ
transfection/NN
yields/NNS
and/CC
may/MD
still/RB
provoke/JJ
an/DT
acute/JJ
immune/JJ
response/NN
./.
====================
Another/DT
mode/NN
of/IN
gene/NN
transfection/NN
makes/VBZ
use/NN
of/IN
DNA-coated/JJ
gold/NN
microparticles/NNS
and/CC
bombarded/VBD
into/IN
a/DT
targeted/VBN
cellular/JJ
surface/NN
by/IN
a/DT
pressure/NN
pulse/NN
of/IN
compressed/VBN
helium/NN
gas/NNS
[/(
304/CD
]/)
./.
====================
These/DT
are/VBP
not/RB
immunogenic/JJ
and/CC
results/VBZ
in/IN
a/DT
very/RB
good/JJ
in/IN
vivo/FW
activity/NN
./.
====================
Electroporation/NN
is/VBZ
also/RB
used/VBN
to/TO
create/VB
transient/JJ
pores/NNS
in/IN
the/DT
lipid/NN
membrane/NN
,/,
allowing/VBG
the/DT
transfection/NN
of/IN
plasmid/NN
DNA/NN
,/,
using/VBG
electric/JJ
field/NN
pulses/NNS
[/(
305/CD
]/)
./.
====================
However/RB
,/,
these/DT
methods/NNS
may/MD
cause/VB
significant/JJ
tissue/NN
damage/NN
during/IN
the/DT
procedure/NN
and/CC
need/VBD
surgery/NN
for/IN
targeted/VBN
internal/JJ
organs/NNS
./.
====================
Gene/NN
transfer/NN
is/VBZ
also/RB
limited/JJ
to/TO
the/DT
targeted/VBN
area/NN
only/RB
./.
====================
Gene/NN
therapy/NN
strategies/NNS
====================
Gene/NN
replacement/NN
using/VBG
cDNA/NN
====================
Gene/NN
replacement/NN
is/VBZ
basically/RB
delivering/VBG
a/DT
functional/JJ
cDNA/NN
with/IN
the/DT
correct/JJ
coding/VBG
sequence/NN
to/TO
supplement/VB
a/DT
nonfunctional/JJ
mutant/JJ
gene/NN
of/IN
interest/NN
in/IN
specific/JJ
cell/NN
types/NNS
[/(
306/CD
]/)
./.
====================
The/DT
ideal/JJ
application/NN
of/IN
gene/NN
replacement/NN
is/VBZ
in/IN
genetic/JJ
disorders/NNS
caused/VBD
by/IN
mutations/NNS
leading/VBG
to/TO
loss/NN
in/IN
phenotype/NN
,/,
such/JJ
as/IN
recessive/JJ
diseases/NNS
./.
====================
However/RB
,/,
effectivity/NN
of/IN
this/DT
gene/NN
therapy/NN
is/VBZ
limited/JJ
by/IN
the/DT
duration/NN
in/IN
which/WDT
gene/NN
is/VBZ
delivered/VBN
during/IN
development/NN
of/IN
target/NN
organs/NNS
./.
====================
If/IN
the/DT
mutation/NN
begins/VBZ
during/IN
prenatal/JJ
development/NN
,/,
gene/NN
replacement/NN
may/MD
not/RB
be/VB
able/JJ
to/TO
recover/VB
normal/JJ
physiology/NN
after/IN
significant/JJ
malformations/NNS
./.
====================
In/IN
addition/NN
,/,
an/DT
extended/JJ
expression/NN
of/IN
the/DT
exogenous/JJ
sequence/NN
must/MD
be/VB
maintained/VBN
if/IN
the/DT
mutated/VBN
gene/NN
is/VBZ
expressed/VBN
into/IN
adulthood/NN
./.
====================
Dominant/JJ
deafness/NN
mutations/NNS
are/VBP
less/RBR
likely/JJ
to/TO
be/VB
recovered/VBN
with/IN
gene/NN
replacement/NN
strategies/NNS
but/CC
other/JJ
approaches/NNS
can/MD
still/RB
be/VB
utilized/VBN
./.
====================
Gene/NN
silencing/NN
using/VBG
RNA/NN
interference/NN
====================
Dominant/JJ
hearing/JJ
loss/NN
mutations/NNS
in/IN
heterozygous/JJ
animals/NNS
can/MD
be/VB
“/CD
silenced/JJ
”/CD
or/CC
negatively/RB
regulated/VBN
by/IN
suppressing/VBG
the/DT
mutant/JJ
allele/NN
while/IN
allowing/VBG
expression/NN
of/IN
the/DT
wild-type/JJ
allele/NN
to/TO
overcome/VB
the/DT
consequences/NNS
of/IN
the/DT
mutation/NN
./.
====================
Gene/NN
silencing/NN
can/MD
be/VB
achieved/VBN
at/IN
the/DT
transcriptional/JJ
level/NN
by/IN
preventing/VBG
the/DT
mRNA/NN
from/IN
being/VBG
transcribed/VBN
./.
====================
At/IN
the/DT
post-transcriptional/JJ
level/NN
,/,
gene/NN
silencing/NN
occurs/VBZ
with/IN
use/NN
of/IN
RNA/NN
interference/NN
(/(
RNAi/NNS
)/)
to/TO
prevent/VB
mRNA/NN
translation/NN
[/(
307/CD
]/)
./.
====================
The/DT
central/JJ
role/NN
in/IN
RNAi/NN
is/VBZ
played/VBN
by/IN
two/CD
types/NNS
of/IN
short/JJ
complementary/JJ
small/JJ
RNA—microRNA/NN
(/(
miRNA/NN
)/)
or/CC
small/JJ
interfering/VBG
RNA/NN
(/(
siRNA/JJ
)/)
./.
====================
In/IN
an/DT
acoustic/JJ
overexposure/JJ
study/NN
in/IN
mouse/NN
,/,
siRNA/JJ
was/VBD
found/VBN
to/TO
be/VB
able/JJ
to/TO
silence/VB
the/DT
expression/NN
of/IN
AMP-activated/JJ
protein/NN
kinase/NN
which/WDT
causes/VBZ
HC/NN
loss/NN
and/CC
cochlear/JJ
synaptopathy/NN
[/(
308/CD
]/)
./.
====================
The/DT
main/JJ
advantage/NN
of/IN
this/DT
method/NN
its/PRP$
sequence/NN
specificity/NN
which/WDT
makes/VBZ
it/PRP
very/RB
suitable/JJ
for/IN
silencing/NN
dominant/JJ
mutations/NNS
without/IN
affecting/VBG
wild-type/JJ
sequences/NNS
or/CC
off/IN
target/NN
sequences/NNS
[/(
309/CD
]/)
./.
====================
Gene/NN
editing/NN
using/VBG
CRISPR/Cas9/NN
system/NN
====================
Another/DT
gene/NN
therapy/NN
approach/NN
that/DT
recently/RB
gained/VBN
much/RB
attention/NN
to/TO
edit/VB
genome/NN
sequences/NNS
is/VBZ
the/DT
use/NN
of/IN
the/DT
CRISPE/Cas9/NN
system/NN
./.
====================
This/DT
approach/NN
is/VBZ
derived/VBN
from/IN
prokaryotic/JJ
immune/JJ
systems/NNS
for/IN
resistance/NN
to/TO
phages/NNS
and/CC
plasmids/NNS
[/(
310/CD
]/)
./.
====================
It/PRP
is/VBZ
the/DT
most/JJS
recent/JJ
and/CC
advanced/JJ
programmable/JJ
nuclease/NN
adapted/VBN
for/IN
genome/NN
engineering/VBG
which/WDT
allows/VBZ
for/IN
the/DT
precise/JJ
direct/JJ
manipulation/NN
of/IN
genome/NN
sequences/NNS
in/IN
the/DT
inner/JJ
ear/JJ
[/(
311/CD
]/)
./.
====================
Engineered/VBN
nuclease-based/JJ
enzymes/NNS
are/VBP
used/VBN
to/TO
find/VB
a/DT
target/NN
genome/NN
sequence/NN
and/CC
to/TO
introduce/VB
single-/JJ
or/CC
double-strand/JJ
DNA/NN
,/,
which/WDT
stimulate/VBP
innate/JJ
DNA/NN
repairing/NN
machinery/NN
./.
====================
CRISPR/Cas/NNS
is/VBZ
considered/VBN
as/IN
the/DT
most/JJS
pervasive/JJ
and/CC
easy-to-use/JJ
system/NN
with/IN
multiple/JJ
applications/NNS
./.
====================
Cas9/NN
require/VBP
the/DT
presence/NN
of/IN
a/DT
protospacer/JJ
adjacent/JJ
motif/NN
(/(
PAM/NN
)/)
immediately/RB
following/VBG
the/DT
DNA/NN
target/NN
sequence/NN
which/WDT
enables/VBZ
the/DT
system/NN
to/TO
be/VB
very/RB
specific/JJ
but/CC
at/IN
the/DT
same/JJ
time/NN
limits/NNS
its/PRP$
clinical/JJ
application/NN
[/(
312/CD
]/)
./.
====================
To/TO
date/NN
,/,
much/RB
effort/NN
has/VBZ
been/VBN
directed/VBN
toward/IN
the/DT
design/NN
of/IN
CRIPSR/NN
nucleases/NNS
with/IN
altered/JJ
PAM/NN
specificities/NNS
and/CC
diminished/VBD
off/JJ
target/NN
activities/NNS
allowing/VBG
even/RB
more/RBR
applications/NNS
[/(
313/CD
]/)
./.
====================
Gene/NN
therapy/NN
is/VBZ
making/VBG
a/DT
comeback/NN
after/IN
safety/NN
concerns/NNS
during/IN
the/DT
late/JJ
1990s/CD
and/CC
early/JJ
2000s/NN
hampered/VBN
research/NN
./.
====================
Gene/NN
therapy/NN
for/IN
genetic/JJ
hearing/NN
loss/NN
is/VBZ
also/RB
getting/VBG
one/CD
step/NN
closer/RB
into/IN
being/VBG
a/DT
clinical/JJ
treatment/NN
after/IN
several/JJ
clinical/JJ
trials/NNS
have/VBP
been/VBN
approved/VBN
but/CC
yet/RB
to/TO
bear/VB
results/NNS
./.
====================
Although/IN
gene/NN
therapy/NN
is/VBZ
a/DT
promising/JJ
treatment/NN
option/NN
,/,
its/PRP$
application/NN
is/VBZ
currently/RB
limited/JJ
by/IN
the/DT
risk/NN
of/IN
side/JJ
effects/NNS
and/CC
is/VBZ
still/RB
under/IN
study/NN
to/TO
ensure/VB
that/DT
it/PRP
will/MD
be/VB
safe/JJ
and/CC
effective/JJ
./.
====================
In/IN
the/DT
meantime/NN
,/,
there/EX
are/VBP
2,597/CD
clinical/JJ
trials/NNS
undertaken/VBN
in/IN
38/CD
countries/NNS
that/DT
have/VBP
been/VBN
either/CC
completed/VBN
,/,
are/VBP
in/IN
progress/NN
,/,
or/CC
approved/JJ
involving/VBG
gene/NN
therapy/NN
[/(
314/CD
]/)
./.
====================
As/IN
we/PRP
wait/VBP
for/IN
preliminary/JJ
results/NNS
to/TO
ongoing/JJ
clinical/JJ
trials/NNS
for/IN
gene/NN
therapy/NN
for/IN
hearing/JJ
loss/NN
,/,
there/EX
are/VBP
already/RB
several/JJ
syndromic/JJ
hearing/JJ
loss/NN
genes/NNS
mentioned/VBN
above/JJ
wherein/IN
gene/NN
therapy/NN
trials/NNS
have/VBP
begun/VBN
for/IN
their/PRP$
corresponding/JJ
syndromes/NNS
./.
====================
These/DT
include/VBP
the/DT
autosomal/JJ
recessive/JJ
gene/NN
MYO7A/NN
causing/VBG
deaf-blindness/NN
in/IN
Usher/NN
syndrome/NN
[/(
315/CD
]/)
./.
====================
Furthermore/RB
,/,
lessons/NNS
from/IN
different/JJ
approaches/NNS
in/IN
gene/NN
therapy/NN
in/IN
other/JJ
systems/NNS
can/MD
greatly/RB
influence/VBP
the/DT
advancement/JJ
in/IN
design/NN
and/CC
implementation/NN
of/IN
gene/NN
therapy/NN
for/IN
genetic/JJ
hearing/NN
loss/NN
./.
====================
Additional/JJ
advances/NNS
are/VBP
expected/VBN
in/IN
the/DT
coming/VBG
years/NNS
as/IN
the/DT
field/NN
of/IN
inner/JJ
gene/NN
therapy/NN
moves/VBZ
toward/IN
the/DT
collective/JJ
goal/NN
of/IN
developing/VBG
novel/JJ
and/CC
effective/JJ
treatments/NNS
for/IN
patients/NNS
with/IN
genetic/JJ
hearing/NN
loss/NN
./.
====================
Inheritance/NN
pattern/NN
of/IN
identified/VBN
genes/NNS
for/IN
genetic/JJ
hearing/NN
loss/NN
./.
====================
Drawn/JJ
with/IN
data/NNS
adapted/VBD
from/IN
Hereditary/JJ
Hearing/JJ
Loss/NN
Homepage/NN
[/(
6/CD
]/)
./.
====================
Autosomal/JJ
recessive/JJ
non-syndromic/JJ
hearing/JJ
loss/NN
genes/NNS
and/CC
loci/NNS
according/VBG
to/TO
Hereditary/JJ
Hearing/JJ
Loss/NN
Homepage/NN
[/(
6/CD
]/)
====================
Autosomal/JJ
dominant/JJ
non-syndromic/JJ
hearing/JJ
loss/NN
genes/NNS
and/CC
loci/NNS
according/VBG
to/TO
Hereditary/JJ
Hearing/JJ
Loss/NN
Homepage/NN
[/(
6/CD
]/)
====================
Other/JJ
non-syndromic/JJ
hearing/JJ
loss/NN
genes/NNS
and/CC
loci/NNS
according/VBG
to/TO
Hereditary/JJ
Hearing/JJ
Loss/NN
Homepage/NN
====================
Syndromic/JJ
hearing/JJ
loss/NN
genes/NNS
according/VBG
to/TO
Hereditary/JJ
Hearing/JJ
Loss/NN
Homepage/NN
[/(
6/CD
]/)
====================
Viral/JJ
vectors/NNS
used/VBN
in/IN
gene/NN
therapy/NN
for/IN
genetic/JJ
hearing/NN
loss/NN
studies/NNS
====================
Non-viral/JJ
vectors/NNS
used/VBN
in/IN
gene/NN
therapy/NN
for/IN
genetic/JJ
hearing/NN
loss/NN
studies/NNS
====================
